TEVA Company Profile
✉ Email this page to a colleague
What is the competitive landscape for TEVA, and when can generic versions of TEVA drugs launch?
TEVA has seven hundred and thirty-eight approved drugs.
There are one hundred US patents protecting TEVA drugs. There are fifty-three tentative approvals on TEVA drugs.
There are nine hundred and twenty-two patent family members on TEVA drugs in forty-nine countries and one thousand and seventy-six supplementary protection certificates in eighteen countries.
Summary for TEVA
| International Patents: | 922 |
| US Patents: | 100 |
| Tradenames: | 510 |
| Ingredients: | 445 |
| NDAs: | 738 |
| Patent Litigation for TEVA: | See patent lawsuits for TEVA |
| PTAB Cases with TEVA as petitioner: | See PTAB cases with TEVA as petitioner |
Drugs and US Patents for TEVA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Pharms Usa | ESCITALOPRAM OXALATE | escitalopram oxalate | TABLET;ORAL | 076765-003 | Mar 14, 2012 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Teva Pharm | AIRDUO DIGIHALER | fluticasone propionate; salmeterol xinafoate | POWDER;INHALATION | 208799-004 | Jul 12, 2019 | RX | Yes | No | 11,439,777 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Teva Parenteral | CYTARABINE | cytarabine | INJECTABLE;INJECTION | 016793-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Teva | UZEDY | risperidone | SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 213586-005 | Apr 28, 2023 | RX | Yes | No | 9,439,905 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TEVA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Teva Pharms Intl | AMRIX | cyclobenzaprine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021777-001 | Feb 1, 2007 | 7,829,121 | ⤷ Sign Up |
| Teva Pharm | AIRDUO RESPICLICK | fluticasone propionate; salmeterol xinafoate | POWDER;INHALATION | 208799-002 | Jan 27, 2017 | 8,006,690 | ⤷ Sign Up |
| Teva Womens | ADDERALL 10 | amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate | TABLET;ORAL | 011522-007 | Feb 13, 1996 | 6,384,020*PED | ⤷ Sign Up |
| Teva Pharm | ARMONAIR RESPICLICK | fluticasone propionate | POWDER;INHALATION | 208798-003 | Jan 27, 2017 | 6,701,917 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for TEVA drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 0.15 mg/0.03 mg/0.01 mg | ➤ Subscribe | 2008-01-22 |
| ➤ Subscribe | Tablets | 0.1 mg/0.02 mg and 0.01 mg | ➤ Subscribe | 2009-11-16 |
| ➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
| ➤ Subscribe | for Injection | 3.5 mg/vial | ➤ Subscribe | 2016-10-26 |
| ➤ Subscribe | Tablets | 0.5 mg and 1 mg | ➤ Subscribe | 2010-05-17 |
| ➤ Subscribe | Extended-release Capsule | 15 mg and 30 mg | ➤ Subscribe | 2008-08-11 |
| ➤ Subscribe | Injection | 40 mg/mL, 1 mL pre-filled syringe | ➤ Subscribe | 2014-01-29 |
| ➤ Subscribe | Tablets | 0.15 mg/0.03 mg | ➤ Subscribe | 2004-03-29 |
| ➤ Subscribe | Tablets | 0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0.15 mg/0.03 mg and 0.01 mg | ➤ Subscribe | 2013-07-10 |
| ➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
| ➤ Subscribe | Tablets | 1 mg/0.02 mg and 75 mg | ➤ Subscribe | 2006-04-17 |
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
| ➤ Subscribe | Tablets | 5 mg, 10 mg, 20 mg, 30 mg | ➤ Subscribe | 2009-11-18 |
| ➤ Subscribe | Injection | 40 mg/mL, 1 mL pre-filled syringe | ➤ Subscribe | 2014-02-26 |
Premature patent expirations for TEVA
International Patents for TEVA Drugs
Supplementary Protection Certificates for TEVA Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1746976 | 17C1027 | France | ⤷ Sign Up | PRODUCT NAME: SEL DE SUCROSOFATE D'IRINOTECAN; REGISTRATION NO/DATE: EU/1/16/1130 20161018 |
| 3351246 | 122019000102 | Germany | ⤷ Sign Up | PRODUCT NAME: EVEROLIMUS; REGISTRATION NO/DATE: EU/1/09/538/001-008 20120723 |
| 1506211 | 179 5017-2014 | Slovakia | ⤷ Sign Up | PRODUCT NAME: KOMBINACIA DAPAGLIFLOZINU ALEBO JEHO FARMACEUTICKY PRIJATELNYCH SOLI A METFORMINU ALEBO JEHO FARMACEUTICKY PRIJATELNYCH SOLI; REGISTRATION NO/DATE: EU/1/13/900/001 - EU/1/13/900/012 20140116 |
| 1663240 | PA2016045 | Lithuania | ⤷ Sign Up | PRODUCT NAME: RILPIVIRINAS + TENOFOVIRO ALAFENAMIDAS; REGISTRATION NO/DATE: EU/1/16/1112 20160621 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
